A recent study adds a new piece to the emerging map of ACE2 biology—an essential entry point exploited by SARS‑CoV‑2 for infection. Researchers report that a previously described “short ACE2” isoform, missing the canonical viral binding domain, is present in human adipose tissue and increases under obesity-related conditions. The finding extends the isoform’s known tissue distribution beyond respiratory epithelium and reproductive, gastrointestinal, and hepatic compartments.
Unlike the full-length ACE2 receptor, this short isoform is engineered by alternative splicing in a way that removes the SARS‑CoV‑2 binding region. That structural difference is crucial for interpreting its function, because it suggests a role that is not centered on direct viral attachment. Instead, the study frames the isoform as a molecule responsive to host signaling pathways shaped by inflammation and immune activity.
The investigators previously noted that interferons—key mediators of antiviral defense—upregulate the short ACE2 isoform in human cells. Building on that observation, the new work specifically asks whether adipose tissue expresses the isoform and whether metabolic disease states modulate its abundance. This is particularly relevant because adipose tissue is increasingly recognized as an immunologically active organ.
To address the question, the authors analyzed adipose tissue samples from women spanning obesity status categories. Molecular profiling was used to detect the short ACE2 transcript and compare expression levels across groups. The results show that the isoform is detectable in human AT and rises in association with obesity.
Mechanistically, the study supports the idea that chronic low-grade inflammation characteristic of obesity may heighten interferon-linked programs in adipose tissue. If so, interferon-stimulated transcription could drive expression of the short ACE2 isoform even in the absence of any viral challenge. This would align with broader evidence that immune signaling reshapes adipose gene expression.
The authors also note that the isoform’s absence of the SARS‑CoV‑2 binding domain could imply functions tied to ACE2-dependent enzymatic or signaling pathways that are distinct from viral entry. Such divergence matters for risk interpretation: expression does not necessarily equate to susceptibility, but it may influence local tissue homeostasis and inflammatory tone.
By identifying short ACE2 in adipose tissue, the work reframes ACE2 as a family shaped by isoform-specific regulation rather than a single receptor entity. It also raises new questions about how metabolic inflammation and interferon signaling interact to regulate ACE2 variants in different organs.
Further studies will be needed to determine whether the short isoform has specific cellular partners in adipose tissue—such as immune cell subsets, stromal cells, or adipocytes themselves—and how its expression changes during weight loss or during interferon-driven immune responses.
Overall, the study provides a targeted, isoform-level view of ACE2 regulation and highlights obesity as a condition that may tune interferon-responsive viral-relevant pathways in human fat tissue.
Subject of Research: ACE2 isoforms in human adipose tissue; interferon regulation and obesity association
Article Title: The short ACE2 isoform is upregulated in adipose tissue from women with obesity
Article References: Salazar, M., Teixeira, D., Oliveira, S.M. et al. The short ACE2 isoform is upregulated in adipose tissue from women with obesity. International Journal of Obesity (2026). https://doi.org/10.1038/s41366-026-02177-1
Image Credits: AI Generated
DOI: 10.1038/s41366-026-02177-1
Keywords: ACE2 isoform; short ACE2; interferons; adipose tissue; obesity
